Home

CRAIG R STAPLETON

CIK 1207106 · See Remarks · last filed 2018-08-02

CRAIG R STAPLETON is a corporate insider who has filed 48 SEC Form 4 insider transactions across 3 companies since 2009. The most recent filing, for AVDL, was dated Aug 2, 2018. Across all open-market trades the lifetime net is +$2.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $8.3M across reported positions. 2 SEC filings were submitted jointly with Stapleton Pharma LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$8.34M

Companies

3

Total Filings

48

Lifetime Open-Market Net

$2.19M

Filer Profile

Reported Address
55 OLD FIELD POINT ROAD
SUITE 2
GREENWICH, CT 06830
Related Filers
Stapleton Pharma LLC — 2 joint filings, latest 2016-06-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Director 588,628 $21.64 $12.74M -$668.0K 14 2018-08-02
ANF Director 57,398 $145.23 $8.34M $942.2K 20 2017-06-16
AVADEL PHARMACEUTICALS PLC (FLML) Delisted Director 508,878 — — $1.92M 8 2017-01-03

Recent Filings

48 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-08-02 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) +27,900 $0 EDGAR
2018-07-11 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) +57,315 $0 EDGAR
2018-03-02 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) — $0 EDGAR
2017-12-19 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) +140,000 $1.21M EDGAR
2017-12-19 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Buy (P) +140,000 $1.21M EDGAR
2017-11-29 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Sell (S) −254,265 -$2.38M EDGAR
2017-09-14 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Buy (P) +20,000 $190.4K EDGAR
2017-06-30 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) — $0 EDGAR
2017-06-16 ANF Exer (M) — $0 EDGAR
2017-05-22 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Buy (P) +31,013 $305.3K EDGAR
Showing 1–10 of 48
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.